This is an aggregated industry headline. Read the full story at FiercePharma →
As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
Amid an intensifying debate over how Washington should counter China’s rapid ascent in the biotech sector, a growing chorus of policymakers and biotech insiders is urging the Treasury Department to expand the newly codified COINS Act to include biotechnology—a move that would extend outbound investm
By FiercePharma
· May 27, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Insulet and Calm are integrating mental health care into diabetes treatment with a series of mindfulness, medi…
The WeekFierceBiotech ↗
Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M
Spero Therapeutics is pivoting to immune and inflammation indications through a license agreement for a CD40L …
The WeekBriefing
Jemperli met its main goal in a phase 2 trial for certain rectal cancers, and GSK now plans to seek U.S. appro…